DOWNSTREAM PROCESSING FEATURED ARTICLES
Novavax, Inc. (Nasdaq:NVAX) today announced that the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) has completed an In-Process Review (IPR) of Novavax' contract covering the company's recombinant virus-like particle (VLP) vaccine candidates for pandemic and seasonal influenza.
-
Proof-Of-Principle For New Drug Development Tool Miicro, Inc.'s results of its Phase I SBIR grant on metabolic neuroimaging for dose evaluation in clinical trials...
-
Sanofi And PATH Announce The Launch Of Large-Scale Production Of Semisynthetic Artemisinin Against Malaria
Sanofi (Euronext: SAN and NYSE: SNY) and PATH’s Drug Development program, established through an affiliation with OneWorld Health, today announced the launch of the large-scale production line of semisynthetic artemisinin at Sanofi’s Garessio site in Italy.
-
GeoVax Announces Enrollment Completion For Phase 1/2 Clinical Trial For HIV/AIDS Therapeutic Vaccine
GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and treat HIV/AIDS, announced it has completed enrollment in a nine-patient Phase 1/2 clinical trial testing the safety, immunogenicity and ability of its DNA/MVA vaccine to elicit protective immune responses in HIV-infected individuals.
DOWNSTREAM PROCESSING WHITE PAPERS & CASE STUDIES
-
White Paper: Capillary Electrophoresis — A Simple Technique
In 1989, Beckman Instruments introduced the first fully automated capillary electrophoresis instrument (P/ACE™ 2000) to the scientific community. At that time, CE demonstrated exceptional resolving of selected compounds, but the new technology lacked a track record of applications. By Beckman Coulter, Inc.
-
Biomanufacturing Complexity
This white paper addresses one of the most serious challenges facing biomanufacturing professionals today - how to understand and then deal with the extreme complexity associated with biotechnology manufacturing.
-
Optimized Purity And Recovery Of A Monoclonal Antibody Using Mixed-Mode Chromatography Media
Monoclonal antibodies (mAbs) remain a predominant class of therapeutic protein products on the market because of their wide range of applications in disease treatment and diagnosis. Over the years, upstream technology advancements have helped improve the titer of target antibodies, from merely 1 g/L two decades ago to 10–13 g/L in fed-batch processes and up to 25 g/L in perfusion cultures today (Gronemeyer et al. 2014).
-
Continuous Biomanufacturing: 10 Reasons Sponsors Hesitate
The industry is abuzz with talk about continuous biomanufacturing (CB), and its virtues have been well described. Here we will look at some of the barriers or concerns perceived to limit its value to the industry. Justified or not, quite a few concerns have been expressed regarding the implementation of this new, rather disruptive technology.
-
Global Biochemical Profiling For Bioprocess Optimization
It is widely understood that the production phase of bioprocessing can have a significant impact on the overall profitability of the biopharmaceutical.
-
Improving DNA Removal from Bioprocess Purification Processes
Many new biological drug products produced using recombinant DNA technology, such as monoclonal antibodies, are produced in cell culture. Because therapeutic proteins such as monoclonal antibodies are produced in cell culture, impurities can result from the host cells, or cell substrates. By 3M Purification Inc.